Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tininurad
- Development stage
- Phase 2
- Lead developer
- Tianjin Institute of Pharmaceutical Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tininurad is a small molecule selective urate transporter 1 (URAT1) inhibitor developed by the Tianjin Institute of Pharmaceutical Research for the treatment of hyperuricemia and gout. By inhibiting URAT1, a transporter protein located in the proximal tubule of the kidney responsible for the majority of uric acid reabsorption, tininurad increases the renal excretion of uric acid, thereby lowering serum uric acid levels. It is currently being evaluated in Phase 2 clinical trials to assess its efficacy and safety in patients with gout and hyperuricemia.
Beyond the preview
Go deeper on tininurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tininurad.